Navigation Links
Novan Announces Promising Results of SB204 Clinical Study
Date:5/30/2013

DURHAM, N.C., May 30, 2013 /PRNewswire/ -- Novan Therapeutics, today announced results from a recent clinical trial demonstrating that nitric oxide releasing drug candidate SB204 reduces colonization of the acne causing bacteria Propionibacterium acnes (P. acnes)  in the skin of healthy volunteers.  This study in combination with Novan's earlier findings regarding sebum production, suggests the formulation may be capable of targeting multiple factors in acne.

(Logo: http://photos.prnewswire.com/prnh/20130228/NE68367LOGO )

The Phase 1, 30-subject study was conducted by Dr. James Leyden (KGL, Inc.). This predictive human model has been used to demonstrate the activity of anti-acne therapies like traditional oral antibiotics and topical antibiotics such as clindamycin.  In this study, twice daily administration of the topical product was safe and "the treatment was extremely well tolerated," added Dr. Leyden.  Several subjects demonstrated a greater than 90 percent reduction of P. acnes when treated with SB204; no vehicle-treated subjects exhibited such a response.  A statistically significant difference (p < 0.05) in P. acnes counts was observed between active and vehicle after two weeks.

Acne is the most common skin disease in the United States, affecting more than 50 million people.  Antibiotics have been a mainstay for dermatologists due to the ability to reduce P. acnes colonization in the skin and the documented ability to treat inflammatory lesions in acne patients.  However, monotherapy usage of these drugs has slowed due to the onset of antibiotic resistance.  Nitric oxide is an antimicrobial with a low propensity for resistance and is part of the human body's natural immune response to bacteria.  "These unique properties of nitric oxide, in conjunction with the potential to reduce sebum, provide the basis for our belief that SB204 has the possibility to transform acne care," says Dr. Nathan Stasko , Novan President .

"I have always said the 'Holy Grail' of acne treatments would be a topical that can influence sebum production or the physicochemical properties of sebum.  If you can do that, the ability to kill P. acnes is icing on the cake," said Dr. Leyden.

SB204 is currently being examined in a Phase 2 study for the treatment of acne.  Results of that study are expected early 2014.

About Novan, Inc.

Novan Inc., based in the Research Triangle Park area of North Carolina, is a clinical-stage drug development company focused on topical delivery of nitric oxide.  Nitric oxide, one of the most studied molecules in human physiology, has been shown to exhibit anti-microbial activity and to promote vasodilation, regulate inflammation, stimulate tissue repair, and even eradicate cancer cells.  The company's proprietary platform technology enables the stable storage and release of nitric oxide in a variety of dosage forms.  Novan is currently developing innovative, first-in-class therapies for the field of dermatology. 

For more information, please contact:

Julia Brannan
Pascale Communications
201-725-7375
novan@pascalecommunications.com
www.novantherapeutics.com

 


'/>"/>
SOURCE Novan Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Novans SB204 Could Be First Topical Sebum Inhibitor
2. Sequenom Announces License And Marketing Agreements With Laboratoire Cerba In France
3. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
4. DMH International Announces EMR Integration to TouchPACS
5. Health Diagnostic Laboratory, Inc. Announces Diabetes Prevention & Management Panel for Early Detection and Treatment of Disease
6. Mylan Specialty L.P. Announces Partnership with Baseball Teams Across Country to Raise Awareness of Potentially Life-Threatening Allergies
7. Simcere Pharmaceutical Group Announces Resignation of Chief Scientific Officer
8. VUCA Health Announces Rapid Adoption of its MedsOnCue Digital Patient Engagement Solution Supporting Health Literacy by Innovative Pharmacies across 19 States
9. Omthera Pharmaceuticals Announces First Quarter 2013 Financial Results
10. Valeant Pharmaceuticals Announces Receipt Of U.S. FDA Complete Response Letter For Efinaconazole
11. ReproCELL Inc. Announces Approval for Listing on the Osaka Stock Exchange JASDAQ Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... -- Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... . ... ... ... Astellas is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):